Gulf Times - Gilead
WHO advises against Gilead's remdesivir for all hospitalised Covid-19 patients

WHO advises against Gilead's remdesivir for all hospitalised Covid-19 patients

Gilead's remdesivir is not recommended for patients hospitalised with Covid-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organisation ...

World's top intensive care body advises against remdesivir for sickest Covid patients

World's top intensive care body advises against remdesivir for sickest Covid patients

Antiviral remdesivir should not be used as a routine treatment for Covid-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a blow to the drug developed by US firm Gilead.

EU buys remdesivir to treat 30,000 Covid patients, seeks more

EU buys remdesivir to treat 30,000 Covid patients, seeks more

The European Union's executive said on Wednesday it had agreed to buy a limited supply of the Covid-19 medicine remdesivir from US drugmaker Gilead to address the short-term needs of European patients

Gilead says remdesivir reduced risk of death in Covid-19 patients, more studies needed

Gilead says remdesivir reduced risk of death in Covid-19 patients, more studies needed

Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill Covid-19 patients.